Can-Fite Anticipates Results from Rheumatoid Arthritis and Dry Eye Syndrome Trials by Year End

Can-Fite BioPharma

is pleased to announce results from two highly-anticipated clinical studies before year-end for Can-Fite's CF101 Drug. The data includes results from the clinical trial of Phase IIb rheumatoid arthritis of Can-Fite and the clinical trial of Phase III dry eye syndrome of OphthaliX Inc.

, in which Can-Fite holds a controlling interest. The expected announcements from the two clinical trials are significant for Can-Fite, as it will shed light on the efficacy and application of its products in the multi-billion dollar healthcare markets. Can-Fite's CF101 addresses a substantial market opportunity highlighting the $12 billion global rheumatoid arthritis market in 2010, which is expected to increase to $18 billion by 2020.  The same study found the psoriasis market to be valued at $3.3 billion in 2010 and is estimated to increase to $6.7 billion by 2018. The results of Phase III trials for dry eye syndrome of OphthaliX Inc.,